Literature DB >> 12222762

Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor.

N A Sharif1, C R Kelly, J Y Crider.   

Abstract

We have determined the agonist activity of a number of natural prostaglandins and prostaglandin analogs at the FP prostaglandin receptor cloned from a human ciliary body cDNA library using phosphoinositide (PI) turnover assays. Travoprost acid (EC50 = 3.2 +/- 0.6 nM) was the most potent agonist in these cells followed by bimatoprost free acid (17-phenyl-trinor PGF2alpha; EC50 = 5.8 +/- 2.6 nM), fluprostenol (EC50 = 6.1 +/- 1.5 nM), and latanoprost free acid (PHXA85; EC50 = 54.6 +/- 12.4 nM) which was 17-fold weaker (p < 0.001) than travoprost acid. Unoprostone and S-1033 were significantly (p < 0.001) weaker than travoprost acid. The amide prodrug, bimatoprost (EC50 = 694 +/- 293 nM), activated this FP receptor with an intermediate potency. The isopropyl ester prodrugs, travoprost (EC50 = 42.3 +/- 6.7 nM), latanoprost (EC50 = 126 +/- 347 nM) and unoprostone isopropyl ester (EC50 = 9,100 +/- 2,870 nM), also exhibited FP agonist activity. However, other compounds such as PGI2, bradykinin, histamine, and serotonin were inactive. The agonist activities of bimatoprost, unoprostone (UF-021), fluprostenol and acids of travoprost and latanoprost were antagonized by AL-8810 (11beta-fluoro- 15-epi-15-indanyl-PGF2alpha), an FP-receptor-selective antagonist (Ki = 1.0 - 2.1 microM; n = 3). These studies have demonstrated, for the first time, agonist activities of the currently known and marketed ocular hypotensive prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12222762     DOI: 10.1089/10807680260218489

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  15 in total

Review 1.  Travoprost/timolol.

Authors:  Sheridan M Hoy; Susan J Keam; Gillian M Keating
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 2.  Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma.

Authors:  Peter G Klimko; Najam A Sharif
Journal:  Br J Pharmacol       Date:  2018-05-17       Impact factor: 8.739

3.  Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.

Authors:  Najam A Sharif
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-05

4.  Interaction of ocular hypotensive agents (PGF2 alpha analogs-bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea.

Authors:  Sudharshan Hariharan; Mukul Minocha; Gyan P Mishra; Dhananjay Pal; Rohit Krishna; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2009-12       Impact factor: 2.671

Review 5.  Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility.

Authors:  Najam A Sharif; Peter G Klimko
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

6.  Travoprost in the management of open-angle glaucoma and ocular hypertension.

Authors:  Philippe Denis; David Covert; Anthony Realini
Journal:  Clin Ophthalmol       Date:  2007-03

7.  First-line treatment for elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension: focus on bimatoprost.

Authors:  Simon K Law
Journal:  Clin Ophthalmol       Date:  2007-09

Review 8.  Prostamides (prostaglandin-ethanolamides) and their pharmacology.

Authors:  D F Woodward; Y Liang; A H-P Krauss
Journal:  Br J Pharmacol       Date:  2007-08-27       Impact factor: 8.739

9.  Effect of prostaglandin analogs: Latanoprost, bimatoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human trabecular meshwork endothelial cells.

Authors:  Jae Young Heo; Yen Hoong Ooi; Douglas J Rhee
Journal:  Exp Eye Res       Date:  2020-03-25       Impact factor: 3.467

Review 10.  Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.

Authors:  Gábor Holló; Andreas Katsanos; Kostas G Boboridis; Murat Irkec; Anastasios G P Konstas
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.